Author response: Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial

Year: 2023

Type: peer-review

Abstract: Third dose of COVID-19 vaccine leads to seroconversion in 56% cancer patients that are seronegative after primary vaccination and a fourth can further boost immune response in patients with hematologic malignancies, which can be predicted by IgM and CD19 levels.

DOI: 10.7554/elife.83694.sa2

Institutions: Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, Montefiore Medical Center, Euroimmun Medizinische Labordiagnostika (Germany)

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Funders: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute

Awards: G1234541941, G1889023266, MINORITY-BASED COMMUNITY ONCOLOGY PROGRAM, G3446497847, G3989356997, G4102728913, G4689185066, G5307235326, G6252953675, G7059131728, G7815908676, G8734902035, G8739450893, Cancer Center Support Grant

OpenAlex ID: W4367018267